Neuropathic Pain Therapy
Neurgain’s novel subpial delivery technology revolutionizes what is possible for pain therapy.
Overcoming Current Challenges in Pain Therapy
Neuropathic pain is widespread, affecting 7-8% of the U.S. population. Whether it is caused by injury or disease, the effects of neuropathic pain are debilitating. Patients experience a range of life-affecting symptoms, whether pain from normally non-painful stimuli (such as touching or brushing against something) or they may experience extreme abnormal sensations that feel like stabbings or electric shocks. Some neuropathic pain patients report burning, coldness, “pins and needles” sensations, numbing or itching.
When neuropathic pain from spinal cord or peripheral nerve injury persists for months or even years, it represents a major clinical problem. And yet, to date, clinicians have been unable to successfully solve this problem for their patients. Patients are typically offered antidepressants or anticonvulsants, such as lidocane or opioid analgesics. As is well known, opiates, while widely used, is ineffective and presents the possibility of troubling additional side effects.
Today, current treatments provide only partial relief from pain to only some 40-60% of patients.
To improve how we treat neuropathic pain, we have created a new system for delivery of therapeutics. The result is better, more precise treatment of neuropathic pain.
Improving Neuropathic Pain Therapy Through Precise Delivery
Neurgain has developed new technology to deliver therapeutics to a targeted location. This unprecedented precision (“precision neurology”) allows clinicians to deliver more accurate dosing of a therapeutic to an exact location within the body.
We call this Precision Neurology.
Neurgain’s innovative spinal subpial delivery technique can now be used to effectively target the specific site of neuropathic pain, for precise gene therapy. Specifically, the technology enables delivery to dorsal horn nociceptive neurons in selected spinal segment(s). We have identified a combination of genes (GAD65 + VGAT) which, after expression in excitatory nociceptive interneurons, led to a potent and long-lasting reversal of neuropathic pain.
Our gene therapy has the potential to provide a new path to how we can treat neuropathic pain for millions of sufferers worldwide.
We are a step closer to provide long-lasting relief from pain.
